Nava-Lacorte A, Martínez-Mier G, González-Velásquez F

Language: Spanish
References: 13
Page: 101-106
PDF size: 238.18 Kb.

ABSTRACT

Objective: To determine whether the use of verapamil in the perfusion solution of the graft has impact in delaying the graft function or slow performance as well as in patient and graft survival. Material and methods: We reviewed the records of patients transplanted from January 2006 to December 2009. During the first two years, verapamil infusion was used and the last two years, it was omitted. Clinical variables were reviewed, kidney function and patient and graft survival. Results: We studied 72 patients, the mean age was 41 ± 11.3 years (range 9-54), predominantly male, 41.7% (n = 30). Two groups were formed based on the use of verapamil in the perfusion solution of the graft: 32 patients used verapamil and 40 in which it was not used. Delayed graft function was 2.8% (n = 2) and slow performance 1.4% (n = 1), all cases found belonged to the group without verapamil. In the verapamil group there was a slight improvement in renal function (creatinine and clearance of it) in the first seven days, after which it was similar in both groups. No significant difference in survival of patients and grafts. Conclusion: Renal graft function was similar in all patients in this study, regardless of the use or not of verapamil, as well as both the graft and patient survival at one year evolution.

REFERENCES

1. Gabriel D. Handbook of kidney transplantation. 4th ed. USA: Lippincott, Williams & Wilkins; 2005.

2. Ginns LC, Benedict A, Morris P. Transplantation. USA: Blackwell Science; 2000.

3. Mühlbacher F, Langer F, Mittermayer C. Preservation solutions for transplantation. Transplant Proc. 1999; 5 (31): 2069-2070.

4. Southard JH, van Gulik TM, Ametani SM, Vreugdenhil PK, Lindell SL, Pieenar BL et al. Important components of the UW solution. Transplantation. 1990; 49: 251-257.

5. Koltuski M, Pawlak J, Hevelke P, Krawczyk M. Assessment of early graft function in relation to different preservation fluids-preliminary results. Ann Transplant. 2003; 8 (4): 31-35.

6. Nguan CY, Sener A, Karnik V, Caumartin Y, House AA, McAllister VC et al . Perfusion of renal allografts with verapamil improves graft function. Transplantation. 2008; 86 (10): 1463-1467.

7. López NF, Jiménez H, Finkelstein LI, Gonzalo VB, Arteaga BAL. Transoperative renal intraarterial verapamil in kidney trasplantation decreases acute tubular necrosis. Transplant Proc. 1999; 31 (7): 3030.

8. Tucci S Jr, Borelli-Bovo TJ, Cologna AJ, Tiraboschi RB, Martins AC, Roselino JE. Calcium channel blocker and renal mitochondrial function in warm renal ischemia. Int Braz J Urol. 2005; 31 (4): 384-389.

9. Shapiro R, Simmons RL, Starzl TE, editors. Renal transplantation. Stamford, CT: Appleton & Lange; 1998.

10. López-Neblina F, Páez-Rollys AJ, Toledo-Pereyra LH. Mechanism of protection of verapamil by preventing neutrophil infiltration in the ischemic rat kidney. J Surg Res. 1996; 61 (2): 469-472.

11. López-Neblina F, Toledo-Pereyra LH, Suzuki S, Mirmiran R. Protective effect of combined allopurinol and verapamil given at reperfusion in severe renal ischemia. J Invest Surg. 1995; 8 (1): 57-63.

12. Nowacki M, Droździk M, Safranow K, Kaminski M, Sulikowski T, Zietek Z et al. Does calcium channel blocker improvement of perfusion impact the functioning of kidney graft in early period after transplantation? Transplant Proc. 2008; 40 (4): 1056-1058.

13. Nakamoto M, Shapiro JL, Mills SD, Schrier RW, Chan L. Improvement of renal preservation by verapamil with 24 hour cold perfusion in the isolated rat kidney. Transplantation. 1988; 2 (45): 313-315.